Current concepts on the surgical and medical management of osteosarcoma

Although advances have been made in both surgical and medical management of patients with osteosarcoma, the overall survival of patients with osteosarcoma has remained constant, with no substantial improvement in the past 15 years. Advances in imaging have had a substantial impact on surgical planning and staging. These advances have, in turn, had a major impact on the surgeon’s ability to perform limb-sparing surgery. Surgical techniques have improved in terms of instrumentation, modularity of implants and availability. Limb salvage has proven to be an acceptable method of treatment both with respect to oncologic and functional outcome in those patients where a wide resection may be achieved. The use of massive allografts has been largely replaced with the use of modern oncologic endoprostheses. Biologic targets that will enable new therapies to have maximum effect on tumor cells while minimizing toxicity to the host tissues need to be identified.

[1]  H. Weinberg,et al.  The Role of Microvascular Surgery in Limb‐Sparing Procedures for Malignant Tumors of the Knee , 1993, Plastic and reconstructive surgery.

[2]  S. Amin,et al.  Limb salvage management of pathologic fractures of primary malignant bone tumors. , 2005, Cancer control : journal of the Moffitt Cancer Center.

[3]  W. Enneking,et al.  The effect of inadvertent tumor contamination of wounds during the surgical resection of musculoskeletal neoplasms , 1988, Cancer.

[4]  W. Winkelmann,et al.  Limb Salvage and Outcome of Osteosarcoma , 1999 .

[5]  M. Gebhardt,et al.  The use of bone allografts for limb salvage in high-grade extremity osteosarcoma. , 1991, Clinical orthopaedics and related research.

[6]  T. Ngoma World Health Organization cancer priorities in developing countries. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  G. Rosen,et al.  Endoprosthetic replacement for stage IIB osteosarcoma. , 1991, Clinical orthopaedics and related research.

[8]  S R Cannon,et al.  Non-invasive distal femoral expandable endoprosthesis for limb-salvage surgery in paediatric tumours. , 2006, The Journal of bone and joint surgery. British volume.

[9]  L. B. Kagen Use of denial in adolescents with bone cancer. , 1976, Health & social work.

[10]  E. Venkatraman,et al.  Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  R. Wilkins,et al.  The Phenix Expandable Prosthesis: Early American Experience , 2001, Clinical orthopaedics and related research.

[12]  Kazutaka Kikuta,et al.  Global Protein-expression Analysis of Bone and Soft Tissue Sarcomas , 2008, Clinical orthopaedics and related research.

[13]  A. Sudo,et al.  Limb salvage for bone sarcoma of the proximal tibia , 1992, International Orthopaedics.

[14]  M. Link,et al.  Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Toshifumi Ozaki,et al.  Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  J. Holland,et al.  Doxorubicin in Disseminated , 1972 .

[17]  J. Armitage Emerging Applications of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor , 1998 .

[18]  K. Starling,et al.  Cis-diamminedichloroplatinum (NSC-119875) in childhood malignancies: a Southwest Oncology Group study. , 1978, Medical and pediatric oncology.

[19]  Toshihiko Yamashita,et al.  ErbB2 expression is correlated with increased survival of patients with osteosarcoma , 2002, Cancer.

[20]  R. Jove,et al.  Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. , 2007, Cancer research.

[21]  G. Blunn,et al.  Stanmore non-invasive growing arthrodesis endoprosthesis in the reconstruction of complicated total knee arthroplasty: A case report. , 2006, The Knee.

[22]  J. Shuster,et al.  The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. , 1986, The New England journal of medicine.

[23]  J. Sloan,et al.  Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  T. Giordano,et al.  Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing's sarcoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  A. Formann,et al.  Quality of life and psychosocial adjustment of young patients after treatment of bone cancer , 1998, Cancer.

[26]  Mike Wilson,et al.  IGF‐1 receptor contributes to the malignant phenotype in human and canine osteosarcoma , 2004, Journal of cellular biochemistry.

[27]  M. Campanacci,et al.  Local recurrence after amputation for osteosarcoma. , 1980, The Journal of bone and joint surgery. British volume.

[28]  Immune responses to the 105AD7 human anti-idiotypic vaccine after intensive chemotherapy, for osteosarcoma , 2005, British Journal of Cancer.

[29]  H. Mankin,et al.  Osteoarticular and intercalary allograft transplantation in the management of malignant tumors of bone , 1982, Cancer.

[30]  R. Grimer,et al.  Endoprosthetic reconstruction for the treatment of musculoskeletal tumors of the appendicular skeleton and pelvis. , 2008, The Journal of bone and joint surgery. American volume.

[31]  M. Varini,et al.  High-dose ifosfamide in advanced osteosarcoma. , 1985, Cancer treatment reports.

[32]  J. Shuster,et al.  Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. , 1991, Clinical orthopaedics and related research.

[33]  M. J. van de Vijver,et al.  Overexpression of the HER-2 oncogene does not play a role in high-grade osteosarcomas. , 2004, European journal of cancer.

[34]  R. Marcove,et al.  Osteogenic sarcoma under the age of twenty-one. A review of one hundred and forty-five operative cases. , 1970, The Journal of bone and joint surgery. American volume.

[35]  G COOPER,et al.  Bone cancer. , 1951, Virginia medical monthly.

[36]  H. Mankin,et al.  Osteoarticular allografts for reconstruction after resection of a musculoskeletal tumor in the proximal end of the tibia. , 1994, The Journal of bone and joint surgery. American volume.

[37]  E. Kleinerman,et al.  Aerosol gemcitabine inhibits the growth of primary osteosarcoma and osteosarcoma lung metastases , 2005, International journal of cancer.

[38]  J. Holland,et al.  Doxorubicin in disseminated osteosarcoma. , 1972, JAMA.

[39]  K. Katz,et al.  Prognostic factors in non-metastatic limb osteosarcoma: A 20-year experience of one center. , 1999, International journal of oncology.

[40]  T. Delaney,et al.  Radiotherapy for local control of osteosarcoma. , 2003, International journal of radiation oncology, biology, physics.

[41]  H. Strander,et al.  Effect of human leukocyte interferon on the growth of human osteosarcoma cells in tissue culture , 1977, International journal of cancer.

[42]  B. Fuchs,et al.  Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines , 2008, Pediatric blood & cancer.

[43]  S. Ferrari,et al.  Local and systemic control for osteosarcoma of the extremity treated with neoadjuvant chemotherapy and limb salvage surgery: the Rizzoli experience. , 2000, Oncology reports.

[44]  M. Malawer,et al.  Constrained Total Scapula Reconstruction After Resection of a High-Grade Sarcoma , 2002, Clinical orthopaedics and related research.

[45]  D. Morton,et al.  Immunologic studies of human sarcomas: Additional evidence suggesting an associated sarcoma virus , 1970, Cancer.

[46]  M. Bernstein,et al.  Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a Pediatric Oncology Group phase II study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  P. Adamson,et al.  Topotecan by 21‐day continuous infusion in children with relapsed or refractory solid tumors: A Children's Oncology Group study , 2006, Pediatric blood & cancer.

[48]  L. Fritz,et al.  A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors , 2003, Nature.

[49]  A. Minami,et al.  Simultaneous reconstruction of bone and skin defects by free fibular graft with a skin flap , 1986, Microsurgery.

[50]  H. Strander Interferons and osteosarcoma. , 2007, Cytokine & growth factor reviews.

[51]  N. Jaffe,et al.  Can cure in patients with osteosarcoma be achieved exclusively with chemotherapy and abrogation of surgery? , 2002, Cancer.

[52]  N. Jaffe,et al.  Adjuvant methotrexate and citrovorum-factor treatment of osteogenic sarcoma. , 1974, The New England journal of medicine.

[53]  C. A. Kuntz,et al.  Improved Survival Associated With Postoperative Wound Infection in Dogs Treated With Limb-Salvage Surgery for Osteosarcoma , 2005, Annals of Surgical Oncology.

[54]  H. Strander,et al.  Influence of Human α-Interferon on Four Human Osteosarcoma Xenografts in Nude Mice , 1985 .

[55]  J. Dubousset,et al.  [Vascularized peroneal reconstruction after bloc resection of tumors or congenital malformations of the upper limb in children]. , 2000, Bulletin de l'Academie nationale de medecine.

[56]  L. Helman,et al.  Rapamycin inhibits ezrin-mediated metastatic behavior in a murine model of osteosarcoma. , 2005, Cancer research.

[57]  S. Ferrari,et al.  Local recurrence and local control of non‐metastatic osteosarcoma of the extremities: A 27‐year experience in a single institution , 2007, Journal of surgical oncology.

[58]  E. Madon,et al.  Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. , 2007, Cellular immunology.

[59]  N. Jaffe,et al.  Concomitant presence of tumor-specific cytotoxic and inhibitor lymphocytes in patients with osteogenic sarcoma. , 1977, The New England journal of medicine.

[60]  E. Pignotti,et al.  Osteosarcoma of the limb. Amputation or limb salvage in patients treated by neoadjuvant chemotherapy. , 2002, The Journal of bone and joint surgery. British volume.

[61]  Haroon-ur-Rasheed,et al.  Autoclaved Tumor Bone for Reconstruction: An Alternative in Developing Countries , 2006, Clinical orthopaedics and related research.

[62]  S. Carter,et al.  The therapy of osteogenic sarcoma: Current status and thoughts for the future , 1972, Journal of surgical oncology.

[63]  S. McCarthy,et al.  En-bloc resection, extracorporeal irradiation, and re-implantation in limb salvage for bony malignancies. , 2005, The Journal of bone and joint surgery. British volume.

[64]  M. Heymann,et al.  Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma‐bearing mice , 2005, Cancer.

[65]  S. Scully,et al.  Direct tendon attachment and healing to porous tantalum: an experimental animal study. , 2007, The Journal of bone and joint surgery. American volume.

[66]  M. Semik,et al.  Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  J. Armitage Emerging applications of recombinant human granulocyte-macrophage colony-stimulating factor. , 1998, Blood.

[68]  A. Huvos,et al.  Expression of HER2/erbB-2 correlates with survival in osteosarcoma. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  H. Horiuchi,et al.  ErbB‐2 expression is correlated with poor prognosis for patients with osteosarcoma , 1996, Cancer.

[70]  R. Kumar,et al.  GM‐CSF‐transduced B16 melanoma cells are highly susceptible to lysis by normal murine macrophages and poorly tumorigenic in immune‐compromised mice , 1999, Journal of leukocyte biology.

[71]  W. Enneking,et al.  A System for the Surgical Staging of Musculoskeletal Sarcoma , 1980, Clinical orthopaedics and related research.

[72]  L. Helman,et al.  Inhibition of the CXCR4/CXCL12 chemokine pathway reduces the development of murine pulmonary metastases , 2007, Clinical & Experimental Metastasis.

[73]  M. Gebhardt,et al.  Survival Data for 648 Patients with Osteosarcoma Treated at One Institution , 2004, Clinical orthopaedics and related research.

[74]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  P. Lin,et al.  Endoprosthetic and Allograft-prosthetic Composite Reconstruction of the Proximal Femur for Bone Neoplasms , 2006, Clinical orthopaedics and related research.

[76]  D. Ludwig,et al.  IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor , 2007, Clinical Cancer Research.

[77]  V. Sondak,et al.  Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[78]  P. Manley,et al.  Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. , 1989, Journal of the National Cancer Institute.

[79]  H J Mankin,et al.  Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. , 2005, The Journal of bone and joint surgery. American volume.

[80]  P. Ravdin,et al.  The c-erbB-2 proto-oncogene as a prognostic and predictive marker in breast cancer: a paradigm for the development of other macromolecular markers--a review. , 1995, Gene.

[81]  J. Squire,et al.  HER2 Amplification and Overexpression Is Not Present in Pediatric Osteosarcoma: A Tissue Microarray Study , 2005, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.

[82]  W. Ebell,et al.  Neoadjuvant chemotherapy for osteogenic sarcoma: results of a Cooperative German/Austrian study. , 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  松山 茂生 Induced Proliferation of Human Osteosarcoma Cells β SB-431542 and Gleevec Inhibit Transforming Growth Factor-Updated , 2003 .

[84]  P. Anderson,et al.  Gemcitabine Radiosensitization after High-Dose Samarium for Osteoblastic Osteosarcoma , 2005, Clinical Cancer Research.

[85]  John Healey,et al.  Upfront window trial of topotecan in previously untreated children and adolescents with poor prognosis metastatic osteosarcoma , 2007, Cancer.

[86]  H. Strander,et al.  Interferon-α as the only adjuvant treatment in high-grade osteosarcoma: Long term results of the Karolinska Hospital series , 2005, Acta oncologica.

[87]  W. Winkelmann,et al.  Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[88]  M. Agarwal,et al.  Limb Salvage Surgery for Osteosarcoma: Effective Low-cost Treatment , 2007, Clinical orthopaedics and related research.

[89]  P. Anderson Effectiveness of radiotherapy for osteosarcoma that responds to chemotherapy. , 2003, Mayo Clinic proceedings.

[90]  Frcs L. M. Jeys MSc,et al.  Post Operative Infection and Increased Survival in Osteosarcoma Patients: Are They Associated? , 2007, Annals of Surgical Oncology.

[91]  H. Kindler The pemetrexed/gemcitabine combination in pancreatic cancer , 2002, Cancer.

[92]  W. Enneking,et al.  The Effect of Contaminated Surgical Margins Revisited , 2002, Clinical orthopaedics and related research.

[93]  E. Mackenzie,et al.  Limb Amputation and Limb Deficiency: Epidemiology and Recent Trends in the United States , 2002, Southern medical journal.

[94]  E. Kleinerman,et al.  Influence of chemotherapy administration on monocyte activation by liposomal muramyl tripeptide phosphatidylethanolamine in children with osteosarcoma. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  W. Winkelmann,et al.  Limb salvage and outcome of osteosarcoma. The University of Muenster experience. , 1999, Clinical orthopaedics and related research.

[96]  E. Jaffee,et al.  Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[97]  H. S. Nicholson,et al.  Late effects of therapy in survivors of childhood and adolescent osteosarcoma. , 1993, Cancer treatment and research.